catalyst calendar
LB PHARMACEUTICALS INC · Data as of 2026-10-25
H1 2027
As we advance toward topline results from our Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027, Susan's deep clinical, regulatory, and development expertise will be instrumental in shaping our development strategy and furthering our ability to deliver innovative new medicines to patients with serious neuropsychiatric disorders.Source filing
H2 2027
The Company expects to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027.Source filing
Q1 2028
The Phase 2 ILLUMINATE-1 trial evaluating the efficacy and safety of LB-102 in patients with bipolar 1 depression is enrolling patients, with topline data expected in the first quarter of 2028.Source filing
H1 2029
Initiation of the Phase 2 trial in the adjunctive treatment of MDD is expected in early 2027, with topline data expected in the first half of 2029.Source filing